Texas Attorney General Taking Steps To Fight Opioid Crisis

Texas, 5 other states sue Purdue Pharma, alleging deception that led to opioid overdose deaths

Texas, 5 other states sue Purdue Pharma, alleging deception that led to opioid overdose deaths

The attorneys general of Texas, Florida, Nevada, North Carolina, North Dakota and Tennessee separately said on Tuesday that they have filed lawsuits against Purdue Pharma LP for its alleged deceptive marketing of prescription painkillers that perpetuated the national opioid crisis.

The lawsuit says Purdue pushed a message of "pseudo-addiction", marketing the idea that people engaged in drug-seeking behavior because they were not receiving enough opioids, and attempted to discredit non-opioid pain relievers by saying medications like aspirin or acetaminophen are riskier for chronic pain.

"There's nothing like talking to a mom who's lost her son from an overdose", Paxton said. Each day, 115 Americans die of opioid overdoses.

Purdue, based in Stamford, Conn., issued a statement in which it denied the accusations and that its drugs were approved by the U.S. Food and Drug Administration and accounted for only 2 percent of all opioid prescriptions.

In September, Paxton announced he was joining a 41-state investigation of companies that manufacture or sell opioids. Also, Nevada and the other litigating states continue to engage in ongoing settlement discussions with Purdue and other companies.

Last year, Shelby County Commissioners filed a lawsuit against almost 20 different drug manufacturers, doctors and pharmacies.

"To more comprehensively address the opioid epidemic in Texas, state leaders must also take concrete steps to improve access to treatment", Villarreal said. Laxalt's office has filed suit against any other pharmaceutical companies.

One of the country's largest pharmaceutical manufacturers knowingly exaggerated claims about the effectiveness of its drugs to mislead Nevada doctors to prescribe more painkilling opioid pills to patients, state Attorney General Adam Laxalt said today.

The suits accused drugmakers of deceptively marketing opioids and the distributors of ignoring indications that the painkillers were being diverted for improper uses. The first trial consolidating three OH cases is set to begin in March 2019 and is considered to be a test of how other lawsuits may shake out.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.